Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

David W.C. Beasley

doi:10.1586/erv.11.47

Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

David W.C. Beasley

Research services

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

Original language	English (US)
Pages (from-to)	601-604
Number of pages	4
Journal	Expert review of vaccines
Volume	10
Issue number	5
DOIs	https://doi.org/10.1586/erv.11.47
State	Published - May 2011

Keywords

West Nile virus
adverse events
elderly
immunogenicity
safety
vaccine

ASJC Scopus subject areas

Immunology
Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1586/erv.11.47

Cite this

@article{28726c2efea84c498f3c9c3c73cf7575,

title = "Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects",

abstract = "Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.",

keywords = "West Nile virus, adverse events, elderly, immunogenicity, safety, vaccine",

author = "Beasley, {David W.C.}",

year = "2011",

month = may,

doi = "10.1586/erv.11.47",

language = "English (US)",

volume = "10",

pages = "601--604",

journal = "Expert review of vaccines",

issn = "1476-0584",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

AU - Beasley, David W.C.

PY - 2011/5

Y1 - 2011/5

N2 - Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

AB - Evaluation of: Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203(1), 75-84 (2011). A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.

KW - West Nile virus

KW - adverse events

KW - elderly

KW - immunogenicity

KW - safety

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=79957592934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957592934&partnerID=8YFLogxK

U2 - 10.1586/erv.11.47

DO - 10.1586/erv.11.47

M3 - Review article

C2 - 21604981

AN - SCOPUS:79957592934

SN - 1476-0584

VL - 10

SP - 601

EP - 604

JO - Expert review of vaccines

JF - Expert review of vaccines

IS - 5

ER -

Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this